Eye care company Alcon acquires Transcend Medical
18 February 2016 | By Victoria White
This Transcend Medical acquisition also expands Alcon's leadership in glaucoma and cataract treatment...
List view / Grid view
18 February 2016 | By Victoria White
This Transcend Medical acquisition also expands Alcon's leadership in glaucoma and cataract treatment...
28 July 2014 | By Novartis
Alcon, the global leader in eye care and a division of Novartis, announced that Simbrinza® eye drops suspension (brinzolamide 10mg/mL and brimonidine tartrate 2mg/mL) has been approved by the European Commission...
18 June 2014 | By Novartis
For its first "Meet Novartis Management" investor day, Novartis gathered more than 20 of its top executives, drawn from the leadership of Pharmaceuticals...
9 April 2014 | By Novartis
Novartis announced the appointment of Jeff George as Division Head of Alcon, effective May 1, 2014...
19 April 2013 | By Novartis
A new beta blocker-free, fixed-combination therapy for glaucoma patients...
18 March 2013 | By Novartis
Alcon announces EU approval of Jetrea®, first and only eye drug to treat sight-threatening vitreomacular traction and macular hole...
18 January 2013 | By Novartis
Jetrea(TM) would become the first drug to treat sight-threatening vitreomacular traction and macular hole...
16 March 2012 | By Novartis
Potential first pharmacological treatment for symptomatic vitreomacular adhesion...
8 April 2011 | By Novartis
Novartis shareholders followed the Board of Directors' recommendation, approving the proposed merger of Alcon, Inc. into Novartis...